FOLD Stock Recent News
FOLD LATEST HEADLINES
Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.
Amicus Therapeutics Inc. (NASDAQ:FOLD ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Daphne Quimi - Chief Financial Officer Sébastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Mitchell Goldman - Chief Medical Officer Ellen Rosenberg - Chief Legal Officer Conference Call Participants Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Ritu Baral - TD Cowen Eliana Merle - UBS Joseph Schwartz - Leerink Partners Dae Gon Ha - Stifel Jeff Hung - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Ethan Markowski - Needham & Company Operator Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Second Quarter 2023 Financial Results Conference Call and webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today.
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2023.
Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
The FDA inspected the WuXi facility this month, and Amicus Therapeutics, Inc. expects approval in the third quarter. Galafold revenue is growing, although the ANDA challenge needs to be resolved.
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates.
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.30 per share a year ago.